



October 10, 2022

To the Members of
Knopp Biosciences LLC

Dear Member:

As we previously reported, earlier this year we sold our Kv7 platform to Biohaven Pharmaceuticals Ltd. ("Biohaven"), and we spun out our dextramipexole ("Dex") program into Areteia Therapeutics, Inc. ("Areteia"). These were transformative deals that we believe will maximize the value of both the Kv7 and Dex assets.

The initial cash consideration from the Biohaven transaction was used primarily to retire outstanding debt and pay our transaction fees and expenses. We also received \$65 million of Biohaven stock, and I am delighted to report that we have now sold the Biohaven shares for nearly \$75 million. We also received our first milestone payment from Biohaven – \$25 million – in connection with the commencement of a human clinical trial for one of the Kv7 activator compounds we sold to Biohaven.

Consistent with Knopp's commitment to distribute such proceeds to its members, the Board of Managers approved a distribution of approximately \$101 million. Of that amount, \$95 million will be paid to the Class C members and will pay in full the Class C Accrued Return as well as the Class C Capital Contribution (the "Class C Preference"). The remainder of the distribution will be paid to the holders of Class 1 Senior Units, Class A Preferred Units, and Class B Preferred Units to cover the taxes attributable to the income/gain allocated to those Units. The Company having paid the Class C Preference, any future distributions would be made in accordance with and have the potential to advance further through the waterfall. Of course, any such distributions are dependent on developments in the Dex and Kv7 programs now in the hands of Areteia and Biohaven, respectively.

Per the Company's Operating Agreement, the tax distribution was calculated using the highest combined federal and state income tax rate applicable to an individual residing in Pennsylvania. An illustration of the distribution by classes and additional tax information prepared by Knopp's accountants accompanies this letter.

All distributions will be made within each class to the owners of record as of October 4, with a tentative distribution date of October 17. All distributions will be made by check and sent by US mail.

Your actual tax situation may vary with respect to this income. Please consult your tax advisor as to your need to make estimated tax payments.

On a final note, I'd like to thank the all the members of Knopp for your commitment over the years. Effective September 30, I resigned as CEO of Knopp Biosciences. It's been a privilege to be part of an exceptional team that through their perseverance and with your support has positioned two remarkable molecules to be difference-making medicines in the lives of patients in the relatively near-term future. Earlier this summer, the two co-founders of Knopp, Greg Hebrank and Tom Petzinger, also resigned their executive positions, Greg having joined Biohaven and Tom now retired. This journey would never have occurred without their vision and leadership. I am also pleased to announce that our long-time general counsel, F.J. Lucchino, has agreed to serve the company as President of Knopp Biosciences. Along with Charlie O'Hanlon, our Vice President, Finance & Investor Relations, the company is in exceptional hands going forward.

Please contact Charlie at charlie@knoppbio.com if you have any questions. Also, F.J. can be reached at fjlucchino@knoppbio.com.

Yours truly,

A handwritten signature in blue ink, appearing to read "M. Bozik". The signature is fluid and cursive, with a long horizontal stroke extending from the "M" and a small flourish at the end.

Michael Bozik

Encls.